Proc (Bayl Univ Med Cent) 2021 Jan 22;34(3):378-379. Epub 2021 Jan 22.
Division of Cardiology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas.
Flecainide is an antiarrhythmic agent indicated for patients with supraventricular arrhythmias without ischemic or structural heart disease. Flecainide toxicity is a rare condition in which patients may present with bradycardia, widening of QRS, PR prolongation, ventricular tachycardia, syncope, malaise, dizziness, visual disturbance, nausea, vomiting, and/or lethargy. It carries an associated mortality rate of approximately 10%. Read More